Akt enzim: új terápiás célpont rákban és cukorbetegségben?

Translated title of the contribution: Akt enzyme: New therapeutic target in cancer and diabetes?

Áron Cseh, B. Szebeni, Balázs Szalay, B. Vásárhelyi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Alteration of apoptotic processes plays a central role in the development and progression of several chronic disorders. Proteins responsible for the regulation of apoptosis are therapeutic targets; these include the Akt enzyme. Akt enzyme is expressed in most cell types. Akt activation is regulated by growth factors, insulin, and also environmental factors as altered oxygen tension and high temperature. Akt is a central regulator of cellular metabolism and survival. Akt function is reportedly altered in some disorders. An increased activity of Akt has been described in prostate, breast, colon, and pancreatic cancer, as well as in hematological malignancies. Akt is also a factor in the pathomechanism of diabetes as it determines beta-cell apoptosis of Langerhans islets and insulin sensitivity of the cells. Several studies revealed that some of the marketed drugs including statins, thiazolidinediones and ACE inhibitors modulate Akt activity. There are efforts to develop specific Akt inhibitors that may improve the efficacy of chemotherapy. Triciribine and perifosine are two Akt inhibitors in developmental phase 1 and 2 that may improve survival in breast cancer, pancreas cancer, gastrointestinal stroma tumor, sarcoma and melanoma, and in hematological malignancy.

Original languageHungarian
Pages (from-to)373-378
Number of pages6
JournalOrvosi Hetilap
Volume150
Issue number8
DOIs
Publication statusPublished - Feb 1 2009

Fingerprint

Pancreatic Neoplasms
Hematologic Neoplasms
triciribine
Enzymes
Apoptosis
Breast Neoplasms
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Thiazolidinediones
Neoplasms
Langerhans Cells
Islets of Langerhans
Angiotensin-Converting Enzyme Inhibitors
Sarcoma
Colonic Neoplasms
Insulin Resistance
Melanoma
Prostatic Neoplasms
Intercellular Signaling Peptides and Proteins
Therapeutics
Insulin

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Akt enzim : új terápiás célpont rákban és cukorbetegségben? / Cseh, Áron; Szebeni, B.; Szalay, Balázs; Vásárhelyi, B.

In: Orvosi Hetilap, Vol. 150, No. 8, 01.02.2009, p. 373-378.

Research output: Contribution to journalArticle

Cseh, Áron ; Szebeni, B. ; Szalay, Balázs ; Vásárhelyi, B. / Akt enzim : új terápiás célpont rákban és cukorbetegségben?. In: Orvosi Hetilap. 2009 ; Vol. 150, No. 8. pp. 373-378.
@article{92fcce5766e7480fb9bc18e30eecc1dd,
title = "Akt enzim: {\'u}j ter{\'a}pi{\'a}s c{\'e}lpont r{\'a}kban {\'e}s cukorbetegs{\'e}gben?",
abstract = "Alteration of apoptotic processes plays a central role in the development and progression of several chronic disorders. Proteins responsible for the regulation of apoptosis are therapeutic targets; these include the Akt enzyme. Akt enzyme is expressed in most cell types. Akt activation is regulated by growth factors, insulin, and also environmental factors as altered oxygen tension and high temperature. Akt is a central regulator of cellular metabolism and survival. Akt function is reportedly altered in some disorders. An increased activity of Akt has been described in prostate, breast, colon, and pancreatic cancer, as well as in hematological malignancies. Akt is also a factor in the pathomechanism of diabetes as it determines beta-cell apoptosis of Langerhans islets and insulin sensitivity of the cells. Several studies revealed that some of the marketed drugs including statins, thiazolidinediones and ACE inhibitors modulate Akt activity. There are efforts to develop specific Akt inhibitors that may improve the efficacy of chemotherapy. Triciribine and perifosine are two Akt inhibitors in developmental phase 1 and 2 that may improve survival in breast cancer, pancreas cancer, gastrointestinal stroma tumor, sarcoma and melanoma, and in hematological malignancy.",
keywords = "Akt, Cancer, Diabetes",
author = "{\'A}ron Cseh and B. Szebeni and Bal{\'a}zs Szalay and B. V{\'a}s{\'a}rhelyi",
year = "2009",
month = "2",
day = "1",
doi = "10.1556/OH.2009.28551",
language = "Hungarian",
volume = "150",
pages = "373--378",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "8",

}

TY - JOUR

T1 - Akt enzim

T2 - új terápiás célpont rákban és cukorbetegségben?

AU - Cseh, Áron

AU - Szebeni, B.

AU - Szalay, Balázs

AU - Vásárhelyi, B.

PY - 2009/2/1

Y1 - 2009/2/1

N2 - Alteration of apoptotic processes plays a central role in the development and progression of several chronic disorders. Proteins responsible for the regulation of apoptosis are therapeutic targets; these include the Akt enzyme. Akt enzyme is expressed in most cell types. Akt activation is regulated by growth factors, insulin, and also environmental factors as altered oxygen tension and high temperature. Akt is a central regulator of cellular metabolism and survival. Akt function is reportedly altered in some disorders. An increased activity of Akt has been described in prostate, breast, colon, and pancreatic cancer, as well as in hematological malignancies. Akt is also a factor in the pathomechanism of diabetes as it determines beta-cell apoptosis of Langerhans islets and insulin sensitivity of the cells. Several studies revealed that some of the marketed drugs including statins, thiazolidinediones and ACE inhibitors modulate Akt activity. There are efforts to develop specific Akt inhibitors that may improve the efficacy of chemotherapy. Triciribine and perifosine are two Akt inhibitors in developmental phase 1 and 2 that may improve survival in breast cancer, pancreas cancer, gastrointestinal stroma tumor, sarcoma and melanoma, and in hematological malignancy.

AB - Alteration of apoptotic processes plays a central role in the development and progression of several chronic disorders. Proteins responsible for the regulation of apoptosis are therapeutic targets; these include the Akt enzyme. Akt enzyme is expressed in most cell types. Akt activation is regulated by growth factors, insulin, and also environmental factors as altered oxygen tension and high temperature. Akt is a central regulator of cellular metabolism and survival. Akt function is reportedly altered in some disorders. An increased activity of Akt has been described in prostate, breast, colon, and pancreatic cancer, as well as in hematological malignancies. Akt is also a factor in the pathomechanism of diabetes as it determines beta-cell apoptosis of Langerhans islets and insulin sensitivity of the cells. Several studies revealed that some of the marketed drugs including statins, thiazolidinediones and ACE inhibitors modulate Akt activity. There are efforts to develop specific Akt inhibitors that may improve the efficacy of chemotherapy. Triciribine and perifosine are two Akt inhibitors in developmental phase 1 and 2 that may improve survival in breast cancer, pancreas cancer, gastrointestinal stroma tumor, sarcoma and melanoma, and in hematological malignancy.

KW - Akt

KW - Cancer

KW - Diabetes

UR - http://www.scopus.com/inward/record.url?scp=65249141186&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65249141186&partnerID=8YFLogxK

U2 - 10.1556/OH.2009.28551

DO - 10.1556/OH.2009.28551

M3 - Article

C2 - 19218147

AN - SCOPUS:65249141186

VL - 150

SP - 373

EP - 378

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 8

ER -